These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 23390011)

  • 1. Targeting the EP1 receptor reduces Fas ligand expression and increases the antitumor immune response in an in vivo model of colon cancer.
    O'Callaghan G; Ryan A; Neary P; O'Mahony C; Shanahan F; Houston A
    Int J Cancer; 2013 Aug; 133(4):825-34. PubMed ID: 23390011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells.
    O'Callaghan G; Kelly J; Shanahan F; Houston A
    Br J Cancer; 2008 Aug; 99(3):502-12. PubMed ID: 18648368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
    Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
    Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinoic acid morpholine amide (RAMA) inhibits expression of Fas ligand through EP1 receptor in colon cancer cells.
    Chen SX; Du SY; Wang YT; Zhao HC; Zhang YL; Yao L
    Tumour Biol; 2016 Jan; 37(1):323-9. PubMed ID: 26211005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer.
    Sharma S; Yang SC; Zhu L; Reckamp K; Gardner B; Baratelli F; Huang M; Batra RK; Dubinett SM
    Cancer Res; 2005 Jun; 65(12):5211-20. PubMed ID: 15958566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity.
    Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J
    Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostaglandin E₂ down-regulates the expression of CD25 on bovine T cells, and this effect is mediated through the EP4 receptor.
    Maślanka T; Spodniewska A; Barski D; Jasiecka A; Zuśka-Prot M; Ziółkowski H; Markiewicz W; Jaroszewski JJ
    Vet Immunol Immunopathol; 2014 Aug; 160(3-4):192-200. PubMed ID: 25001909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome.
    Nüsing RM; Treude A; Weissenberger C; Jensen B; Bek M; Wagner C; Narumiya S; Seyberth HW
    J Am Soc Nephrol; 2005 Aug; 16(8):2354-62. PubMed ID: 15976003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
    Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
    Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of CD4(+) and CD8(+) anti-tumor effector T cell responses by bacteria mediated tumor therapy.
    Stern C; Kasnitz N; Kocijancic D; Trittel S; Riese P; Guzman CA; Leschner S; Weiss S
    Int J Cancer; 2015 Oct; 137(8):2019-28. PubMed ID: 25868911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor.
    Duffy MM; Pindjakova J; Hanley SA; McCarthy C; Weidhofer GA; Sweeney EM; English K; Shaw G; Murphy JM; Barry FP; Mahon BP; Belton O; Ceredig R; Griffin MD
    Eur J Immunol; 2011 Oct; 41(10):2840-51. PubMed ID: 21710489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin (IL)-24 transforms the tumor microenvironment and induces anticancer immunity in a murine model of colon cancer.
    Ma YF; Ren Y; Wu CJ; Zhao XH; Xu H; Wu DZ; Xu J; Zhang XL; Ji Y
    Mol Immunol; 2016 Jul; 75():11-20. PubMed ID: 27209087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD11c(high)CD8+ regulatory T cell feedback inhibits CD4 T cell immune response via Fas ligand-Fas pathway.
    Chen Z; Han Y; Gu Y; Liu Y; Jiang Z; Zhang M; Cao X
    J Immunol; 2013 Jun; 190(12):6145-54. PubMed ID: 23677464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
    Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
    J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
    Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
    Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE; Shanahan F; O'Connell J; Houston AM
    Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells.
    Kurooka M; Kaneda Y
    Cancer Res; 2007 Jan; 67(1):227-36. PubMed ID: 17210703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases.
    Grimm M; Gasser M; Bueter M; Strehl J; Wang J; Nichiporuk E; Meyer D; Germer CT; Waaga-Gasser AM; Thalheimer A
    BMC Cancer; 2010 Mar; 10():82. PubMed ID: 20205946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13.
    Park JM; Terabe M; van den Broeke LT; Donaldson DD; Berzofsky JA
    Int J Cancer; 2005 Mar; 114(1):80-7. PubMed ID: 15523692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.